In a report released today, Joseph Stringer from Needham assigned a Buy rating to Alnylam Pharma (ALNY – Research Report), with a price target of $180.00. The company’s shares closed last Tuesday at $177.06, close to its 52-week high of $184.83.
According to TipRanks.com, Stringer has 0 stars on 0-5 stars ranking scale with an average return of -13.0% and a 22.1% success rate. Stringer covers the Healthcare sector, focusing on stocks such as Lexicon Pharmaceuticals, Phathom Pharmaceuticals, and Apellis Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Alnylam Pharma with a $187.33 average price target, representing a 4.6% upside. In a report released today, Stifel Nicolaus also maintained a Buy rating on the stock with a $193.00 price target.
The company has a one-year high of $184.83 and a one-year low of $119.29. Currently, Alnylam Pharma has an average volume of 605.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.